[1]王 倩,蒋思雨,刘倩希,等.加味麦门冬汤联合安罗替尼治疗晚期驱动基因阴性非小细胞肺癌临床疗效[J].陕西中医,2024,(8):1048-1051.[doi:DOI:10.3969/j.issn.1000-7369.2024.08.008]
　WANG Qian,JIANG Siyu,LIU Qianxi,et al.Clinical efficacy of modified Maimendong decoction combined with anlotinib on advanced driver gene-negative non-small cell lung cancer[J].,2024,(8):1048-1051.[doi:DOI:10.3969/j.issn.1000-7369.2024.08.008]
点击复制

加味麦门冬汤联合安罗替尼治疗晚期驱动基因阴性非小细胞肺癌临床疗效
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年8期
页码:
1048-1051
栏目:
临床研究
出版日期:
2024-08-05

文章信息/Info

Title:
Clinical efficacy of modified Maimendong decoction combined with anlotinib on advanced driver gene-negative non-small cell lung cancer
作者:
王 倩1; 蒋思雨1; 刘倩希1; 程 帅1; 袁 江1; 陈璐璐1; 赵陆轶1; 何 广1; 刘松江2
(1.黑龙江中医药大学,黑龙江 哈尔滨 150040; 2.黑龙江中医药大学附属第一医院肿瘤科,黑龙江 哈尔滨 150040)
Author(s):
WANG Qian; JIANG Siyu; LIU Qianxi; CHENG Shuai; YUAN Jiang; CHEN Lulu; ZHAO Luyi; HE Guang; LIU Songjiang
(Heilongjiang University of Chinese Medicine,Harbin 150040,China)
关键词:
肺癌;  麦门冬汤;  安罗替尼;  气阴两虚;  晚期;  肿瘤标志物
Keywords:
Lung cancer;  Maimendong decoction;  Anlotinib;  Qi and yin deficiency;  Advanced;  Tumor markers
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7369.2024.08.008
文献标志码:
A
摘要:
目的:探究加味麦门冬汤联合安罗替尼对气阴两虚型晚期驱动基因阴性非小细胞肺癌(NSLC)的临床疗效。方法:回顾性分析接受安罗替尼治疗的气阴两虚型晚期驱动基因阴性NSLC患者的临床资料,按是否联合加味麦门冬汤治疗分为观察组(n=57)及对照组(n=55)。比较两组患者临床疗效及不良反应发生情况,观察治疗前及治疗3个疗程后两组患者中医证候积分、血清肿瘤标志物水平[癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA-21)、糖类抗原125(CA125)]、疾病相关生化指标[血管内皮生长因子(VEGF)、血小板衍生生长因子(PDGF)]、生存质量[卡氏功能状态评分(KPS)]变化,并比较治疗1年后两组患者生存情况。结果:治疗3个疗程后,观察组临床总有效率、KPS评分明显高于同期对照组(均P<0.05),血清肿瘤标志物、疾病相关生化指标水平显著低于同期对照组(均P<0.05)。治疗1年后,观察组生存率高于同期对照组(P<0.05)。两组患者不良反应比较差异无统计学意义(P>0.05)。结论:加味麦门冬汤联合安罗替尼能够改善气阴两虚型晚期驱动基因阴性NSLC患者证候,降低血清肿瘤标志物水平,抑制肿瘤细胞转移,提高患者生存质量,且不良反应较少。
Abstract:
Objective:To explore the clinical efficacy of modified Maimendong decoction combined with anlotinib in the treatment of advanced driver gene-negative non-small cell lung cancer(NSLC)of qi and yin deficiency.Methods:The clinical data of patients with advanced driver gene-negative NSLC of qi and yin deficiency type were retrospectively analyzed.They were divided into observation group(n=57)and control group(n=55)according to whether they were treated with Maimendong decoction or not.The clinical efficacy and occurrence of adverse reactions,TCM syndromes scores,serum tumor markers [carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA-21),carbohydrate antigen 125(CA125)],disease-related biochemical indicators [vascular endothelial growth factor(VEGF),platelet-derived growth factor(PDGF)] and quality of life [Karnofsky Performance Status(KPS)] before treatment and after 3 courses of treatment and survival status after 1 year of treatment were compared between both groups of patients.Results:After 3 courses of treatment,the clinical effective rate and KPS score in observation group were significantly higher than those in control group(all P<0.05),while the levels of serum tumor markers and disease-related biochemical indicators were significantly lower than those in control group(all P<0.05).The survival rate in observation group after 1 year of treatment was higher than that in control group(P<0.05).There were no significant differences in adverse reactions between the two groups(P>0.05).Conclusion:Modified Maimendong decoction combined with anlotinib can improve the syndrome of qi and yin deficiency of advanced driver gene negative NSLC patients,reduce the level of serum tumor markers,inhibit tumor cell metastasis,improve the quality of life of patients,and have fewer adverse reactions.

参考文献/References:

[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] 夏宇,陈英耀,杨毅.晚期非小细胞肺癌间接经济负担及其影响因素分析[J].中国卫生经济,2023,42(8):70-73.
[3] TRAVIS W D,BRAMBILLA E,BURKE A P,et al.Introduction to the 2015 world health organization classification of tumors of the lung,pleura,thymus,and hear[J].J Thorac Oncol,2015,10(9):1240-1242.
[4] 王华寿,卢陈嘉,黄俊文,等.肺癌组织环指蛋白181、转移相关基因1、血管内皮生长因子C表达及与患者临床病理特征和预后相关性分析[J].陕西医学杂志,2023,52(1):110-113.
[5] 陈沁阳,张杰,谢晓慧,等.SMARCA4/BRG1缺陷型非小细胞肺癌的临床病理特点和治疗策略[J].中国肿瘤临床,2022,49(3):155-158.
[6] 苗丽丽,蒋士卿.中医药治疗小细胞肺癌的研究进展[J].现代中西医结合杂志,2022,31(19):2766-2769.
[7] 胡云中,刘彭坤,胡忠慧,等.安罗替尼联合DP方案治疗晚期非小细胞肺癌的临床研究[J].现代药物与临床,2022,37(11):2556-2561.
[8] 苏坤,徐培培.清金化痰汤加减联合化疗对晚期肺癌患者中医症状积分及血清CYFRA21-1水平的影响[J].陕西中医,2024,45(4):511-515.
[9] 包瑜,张培彤.原发性支气管肺癌中医证候研究现状评述[J].环球中医药,2022,15(7):1273-1279.
[10] 王军徽,肖萌,马功贤,等.非小细胞肺癌中医药治疗研究进展[J].陕西中医,2023,44(11):1663-1664.
[11] 柳云飞,王延朋,陈涛利,等.清肺化痰汤联合安罗替尼对痰热阻肺证中晚期小细胞肺癌化疗患者肿瘤特异因子及免疫功能的影响[J].辽宁中医杂志,2022,49(12):76-79.
[12] 石远凯,孙燕,于金明,等.中国晚期原发性肺癌诊治专家共识(2016年版)[J].中国肺癌杂志,2016,19(1):1-15.
[13] 沈自尹,王文健.中医虚证辨证参考标准[J].中国中西医结合杂志,1986,6(10):598.
[14] 中华人民共和国卫生部.中药新药临床研究指导原则试行[M].北京:中国医药科技出版社,2002:361-390.
[15] 国家技术监督局.中华人民共和国国家标准中医临床诊疗术语:证候部分[M].北京:中国标准出版社,1997:65.
[16] 叶亚兰,孟凡亮,仰杰.CCL25和LTBP2在非小细胞肺癌患者血清中的表达及在疾病诊断中的应用价值[J].临床肺科杂志,2022,27(9):1403-1406,1410.
[17] 高娜,王崇宝.胸腺肽联合顺铂、培美曲塞二钠治疗晚期非小细胞肺癌临床疗效研究[J].陕西医学杂志,2022,51(11):1424-1427.
[18] 杨济纲,刘鹏,江洋,等.肺癌患者癌因性疲乏的中医病机及证候探讨[J].现代中医临床,2023,30(2):113-116.
[19] 张楠,胡燕,范建,等.益气解毒方联合表皮生长因子受体络氨酸激酶抑制剂靶向治疗气阴两虚型非小细胞性肺癌患者的疗效观察[J].世界中西医结合杂志,2023,18(2):401-405.
[20] 杨晓慧,臧海洋,顾小侠,等.麦门冬汤基于调节肿瘤相关巨噬细胞表型抑制肺癌增殖转移的机制研究[J].辽宁中医杂志,2022,49(9):148-151.
[21] 操思源,宋文灿,陶正平.信迪利单抗联合盐酸安罗替尼用于晚期非小细胞肺癌疗效研究[J].临床和实验医学杂志,2022,21(4):356-360.
[22] 魏娜,张晓智.盐酸安罗替尼或甲磺酸阿帕替尼治疗晚期实体恶性肿瘤疗效及对患者凝血功能的影响[J].陕西医学杂志,2021,50(7):871-874.
[23] 李首崇.MSCT联合血清CYFRA21-1、NSE、CA125检测对肺癌的诊断价值[J].中国CT和MRI杂志,2022,20(7):37-39.
[24] 蔡玉亮,郑杰,张金花,等.华蟾素介导miR-497-5p/VEGFA通路调控肺癌细胞的增殖、凋亡及血管生成[J].现代肿瘤医学,2023,31(4):632-637.
[25] 夏冰天,何芳,宋冰欣,等.伊马替尼通过PDGF/PDGFR通路对A549非小细胞肺癌裸鼠移植瘤的抑制作用及机制研究[J].肿瘤防治研究,2023,50(9):854-859.

相似文献/References:

[1]刘海涛 ,衣秀秀,田建辉△.肺癌中西医抗凝治疗研究进展*[J].陕西中医,2020,(1):127.
[2]邵翠丽,周晋华△,杨勤军,等.周晋华运用环磷酰胺联合中药紫杉治疗晚期肺癌经验*[J].陕西中医,2020,(2):223.
　SHAO Cuili,ZHOU Jinhua,YANG Qinjun,et al.ZHOU Jinhua treats advanced lung cancer with cyclophosphamide and purple shirt[J].,2020,(8):223.
[3]汪 莉,杜红旭,周正国,等.攻癌固真汤联合吉非替尼治疗肺癌气虚血瘀证疗效及对患者血流状态的影响[J].陕西中医,2021,(3):338.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.017]
　WANG Li,DU Hongxu,ZHOU Zhengguo,et al.Clinical effect of Gong'ai Guzhen decoction combined with gefitinib in treating lung cancer with Qixu Xueyu syndrome and affect blood flow state[J].,2021,(8):338.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.017]
[4]郑 茜,刘远婷,丁甜甜,等.消积抑癌方对Lewis肺癌荷瘤小鼠MMP-2的影响[J].陕西中医,2021,(7):844.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.007]
　ZHENG Qian,LIU Yuanting,DING Tiantian,et al.Effect of Xiaoji Yi'ai recipe on MMP-2 in Lewis lung cancer bearing mice[J].,2021,(8):844.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.007]
[5]刘文佳,刘宗凯,初晓苏,等.山慈菇-王不留行干预肺癌向骨转移过程生物信息学作用机制[J].陕西中医,2021,(9):1302.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.041]
[6]杨 昕,李和根.肺癌辨证分型研究进展[J].陕西中医,2021,(9):1313.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.043]
　YANG Xin,LI Hegen.Progress in syndrome differentiation of lung cancer[J].,2021,(8):1313.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.043]
[7]李 健,贾 瑞,王 超,等.健脾益气汤联合化疗对肺癌术后患者免疫功能的影响[J].陕西中医,2023,(4):459.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.011]
　LI Jian,JIA Rui,WANG Chao,et al.Effect of Jianpi Yiqi decoction combined with chemotherapy on immune function in patients with lung cancer after surgery[J].,2023,(8):459.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.011]
[8]宁永波,王雅兴,陈香颖,等.名中医王瑞平“期证相合”理论在肺癌术后研究肿瘤微环境经验[J].陕西中医,2023,(10):1448.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.026]
　NING Yongbo,WANG Yaxing,CHEN Xiangying,et al.Wang Ruiping's theory of “phase correspondence” in postoperative lung cancer patients[J].,2023,(8):1448.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.026]
[9]张 尤,陈 炜.名中医韩明向基于“一本四证”论治肺癌经验[J].陕西中医,2023,(12):1788.[doi:DOI:10.3969/j.issn.1000-7369.2023.12.027]
[10]陈香颖,宁永波,王雅兴,等.名中医王瑞平运用“培土生金法”治疗肺癌经验[J].陕西中医,2024,(4):536.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.023]
　CHEN Xiangying,NING Yongbo,WANG Yaxing,et al.Experience of professor Wang Ruiping using “tonifying the spleen and replenishing the lung” to treat lung cancer[J].,2024,(8):536.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.023]

备注/Memo

备注/Memo:
基金项目:黑龙江省中医药科技项目(GY2022-05)
更新日期/Last Update: 2024-08-08